Kobay Technology eyes growth in contract manufacturing, advanced technologies
Revenue for the quarter stood at RM81.4 million compared to RM87.8 million posted in Q3 FY24 due to a shift in sales towards a lower-margin product mix and subdued market demand for higher-margin products during the quarter.
For the nine-month (9M) period, Kobay recorded an 8.2% year-on-year (YoY) increase in revenue, reaching RM257.3 million compared to RM237.8 million in the 9M of FY24.
The growth was primarily driven by commendable growth in the manufacturing segment, which saw a 10.9% YoY rise in revenue to RM164.2 million in 9M FY25, up from RM148.1 million in 9M FY24.
Higher sales orders across the core mainly propelled this improvement in manufacturing business units, though this was partially offset by a softer demand for higher-margin products and the incubating project, which contributed substantially, resulting in a lower margin recorded.
Profit before tax (PBT) for the manufacturing segment rose by 2.7% YoY to RM11.7 million, versus RM11.4 million in 9M FY24.
Reflecting the top-line performance, the group's net profit for 9M FY25 saw a modest climb of 0.9% YoY to RM10.2 million vis-à-vis RM10.1 million in 9M FY24.
Managing Director and CEO Datuk Seri Koay Hean Eng said the company's 9M FY25 results highlight the group's resilience amid a challenging and volatile operating environment, characterised by tariffs, export controls, and supply chain restrictions that continue to affect the global economy.
He said this policy uncertainty complicates investment and manufacturing decisions, potentially impacting long-term capacity planning.
On a brighter note, Koay said the global semiconductor industry continues to show vitality, with the Semiconductor Industry Association (SIA) reporting an 18.8% YoY increase in global semiconductor sales to US$167.7 billion in the first quarter of 2025.
The World Semiconductor Trade Statistics (WSTS) also projects the industry to reach approximately US$697 billion this year, an 11.2% surge.
'Against this backdrop, the group is actively advancing its diversification efforts into the contract manufacturing (CM) services as part of our broader strategic approach to adapt to market conditions.
'These efforts, combined with investments in advanced manufacturing technologies, are expected to drive long-term growth and stabilise performance on a YoY basis.
'Alongside these efforts, we remain optimistic about the prospects of our property development division. This outlook is fuelled by ongoing infrastructure projects, government initiatives, and a revival in tourism activity, all expected to bolster property markets in key locations such as Langkawi and Penang.
'Moving forward, we intend to time upcoming product launches to align with evolving buyer trends while exercising prudent risk management and maintaining operational discipline.
'Our pharmaceutical and healthcare division expects steady demand in the future, supported by growing health awareness, preventive care trends, and demographic changes such as an ageing population.
'Nevertheless, inflation and rising living costs may weigh on consumer appetite soon. To navigate this, we are expanding our product range, exploring new market segments such as high-margin niche medical products, improving operational efficiency, and strengthening our digital marketing efforts to enhance brand presence.
'As we progress, we will prioritise agility and responsiveness as essential for navigating an increasingly complex and dynamic market landscape. By remaining adaptable and proactive, we aim to manage challenges effectively while building sustainable growth over time,' Koay said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
30 minutes ago
- The Star
IHH eyes upside with Turkiye hospital acquisition
PETALING JAYA: Turkiye remains a growth engine for IHH Healthcare Bhd , underpinned by the strong occupancy rate of its hospitals there. BIMB Research in a report said Turkiye's largest hospital operator, Acibadem, which is majority-owned by IHH Healthcare Bhd, is operating at 75% occupancy. Revenue in the first quarter of financial year 2025 (1Q25) per inpatient admission rose 16% year-on-year on a constant currency basis to RM12,355, driven by a more acute case mix. 'Inpatient admissions totalled 44,311 in 1Q25, with foreign patients contributing 13% of revenue.' The research house said earnings before interest, taxes, depreciation and amortisation (Ebitda) for Turkiye came in at RM362mil, with a 300 basis points margin drop due to pre-operating costs from Acibadem Kartal and Vitosha, as well as Ramadan seasonality. Looking ahead, growth will be supported by the Bayındır acquisition. 'The Bayındır acquisition brings urban market exposure and potential procurement and operational synergies, and is supported by a pipeline to add 1,030 beds (circa additional 16%) by 2028, in line with rising demand for quality healthcare.' Acibadem announced earlier this week that it had agreed to buy an 80% stake in Bayındır Hospitals from Is Bankasi for US$55mil (RM232.2mil). BIMB Research said the acquisition offers Acibadem immediate capacity expansion, access to new catchment areas, and synergies in procurement and clinical standards, while also tapping into Turkiye's growing healthcare demand, supported by demographic trends and government initiatives. 'Retaining Turkiye Is Bankasi as a minority shareholder reduces political and operational risks while leveraging its local expertise. 'This transaction also strengthens IHH's diversification outside Malaysia, increasing its resilience against market-specific shocks.' BIMB Research said the financial impact to IHH in the near term is likely modest due to the relatively small scale of Bayındır's operations within the group. 'Integration risks remain, especially in aligning systems, regulatory compliance, and corporate culture. 'The deal comes amid continued Turkyish lira volatility, which may affect earnings translation. Nonetheless, the acquisition price appears reasonable given the asset scale and strategic location, though further disclosures on Bayındır's revenue, Ebitda and occupancy rates would help in refining our forecasts.' The research house is maintaining a 'buy' call on IHH with an unchanged target price of RM8.60. 'At this stage, we maintain our financial year 2025 (FY25) to FY26 forecasts pending completion and integration updates. 'The acquisition supports IHH's long-term growth profile but does not immediately alter earnings trajectory. 'Key monitors include post-merger performance, patient volumes, margin trends, and foreign exchange management. 'Given the group's strong balance sheet and execution track record in cross-border acquisitions, we view the move as a strategic positive but will reassess our target price upon receiving more financial details from management.'
The Star
an hour ago
- The Star
Oil climbs 2% as Fed rate cut, Trump-Putin talks loom
Brent crude futures rose US$1.21, or 1.8%, to settle at US$66.84 a barrel, while US West Texas Intermediate (WTI) crude rose US$1.31, or 2.1%, to settle at US$63.96. NEW YORK: Oil prices climbed about 2% to a one-week high on Thursday after US President Donald Trump warned of "severe consequences" if his talks with Russian President Vladimir Putin on Ukraine fail, and on optimism that a likely US interest rate cut next month could spur oil demand. Central banks, like the US Federal Reserve, use interest rates to control inflation. Lower rates reduce consumer borrowing costs and can boost economic growth and demand for oil. Brent crude futures rose US$1.21, or 1.8%, to settle at US$66.84 a barrel, while US West Texas Intermediate (WTI) crude rose US$1.31, or 2.1%, to settle at US$63.96. Those price gains pushed both crude benchmarks out of technically oversold territory for the first time in three days, and led Brent to its highest close since August 6. On Tuesday, Brent closed at its lowest price since June 5 and WTI closed at its lowest price since June 2 due in part to bearish inventory and supply data from the US Energy Information Administration and the International Energy Agency. Trump said on Thursday he thought Putin was ready to make a deal on ending his war in Ukraine after the Russian president floated the prospect of a nuclear arms agreement on the eve of their summit in Alaska. But on Wednesday, Trump threatened "severe consequences" if Putin does not agree to peace in Ukraine, without elaborating. Trump has warned of economic sanctions if the meeting on Friday proves fruitless. Russia was the second-biggest producer of crude in 2024 behind the US, so any agreement that could ease sanctions on Moscow would likely boost the amount of Russian oil available for export to global markets. Trump has threatened to enact secondary tariffs on buyers of Russian crude, primarily China and India, if Russia continues its war in Ukraine. "The uncertainty of US-Russia peace talks continues to add a bullish risk premium given Russian oil buyers could face more economic pressure," Rystad Energy said in a client note. Some analysts, however, remained sceptical that Trump would take action that could significantly disrupt oil supplies. Expectations that the Fed will cut rates in September also propped up oil prices. Traders mostly believe a cut will happen next month after US consumer prices increased at a moderate pace in July. US Treasury Secretary Scott Bessent said he thought an aggressive half-percentage-point cut was possible given recent weak employment numbers. But a jump in wholesale prices is likely to bolster concerns among Fed policymakers that rising inflation remains a risk, intensifying debate over the rationale for an rate cut next month and leaving the tension between the US central bank and the White House unresolved. In Europe, Norwegian oil and gas investments are expected to peak this year and start declining in 2026 as major projects are completed, a statistics office survey of industry players showed on Thursday. Norway produces about 2% of global oil. It became Europe's largest supplier of pipeline gas after Russia's invasion of Ukraine in February 2022. — Reuters
The Star
2 hours ago
- The Star
China pharma firms turn to local reagent suppliers to cut costs
PHARMACEUTICAL research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers say, as they seek to cut costs and delivery times. Western reagent suppliers including US-based Thermo Fisher Scientific and Germany's Merck have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control. But rising Chinese import tariffs due to the trade war with the United States and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific and Nanjing Vazyme Biotech instead, the executives and managers said. The five who spoke to Reuters work at Chinese firms involved in the purchase or supply of reagents and their comments are an early sign of an expected industry shift toward more Chinese purchases. China's reagent market for lab and diagnostic use has been to some extent supplied by imports, which were valued at US$5.76bil in 2024, down slightly from US$5.83bil in 2023, according to UN Comtrade data. 'It is actually more advantageous (for reagents to be local) because the timeliness requirement is high,' said Ma Xingquan, co-president of pharmaceutical research firm ChemPartner PharmaTech. Most reagents it uses in its pre-clinical work are products that are made in China by firms including Titan and Shanghai Aladdin Biochemical Technology, he said. ChemPartner's usage of locally made reagents would probably increase further as new products become available, Ma added. The rush to use domestically made reagents has accelerated since April, the month China raised duties on US goods to 125%, a manager at Titan and an executive at Vazyme said, though the levies have since been lowered as Beijing and Washington continue trade talks. Some Chinese drugmakers were worried about tariff policy uncertainty, Titan product manager Yang Dong said. Since April, more than 90% of Vazyme's customers have discussed replacing imported reagents with its products, Vazyme senior vice-president Xu Xiaoyu said. 'Before April, customers were only saying long term, they hope to be able to replace (reagents) with those locally made, it would be better,' Xu said. 'But to customers these tariffs are like a shock in a short period of time. They clearly felt this type of direct impact ... their impetus (for replacement) will be stronger.' Titan and Vazyme are both forecast to report strong sales growth this year, according to brokers. China International Capital Corp expects Titan's annual revenue to grow 22% to 3.52 billion yuan (US$490mil) this year, while Vazyme's revenue is set to rise 15% to 1.59 billion yuan over the same period, according to Soochow Securities. 'There is still a lot of room for substitution of imported biological reagent enzymes, clients are strongly interested in locally-made replacements,' Soochow said in a recent note. Shares in Titan and Vazyme have risen about 54% and 18% respectively since the start of the year. Merck and Thermo Fisher shares have fallen about 21% and 8% respectively over the same period. Morningstar analyst Max Jousma expects China's reagents market to grow more than 10% annually over the next five years, driven by government support for the biotech and pharmaceutical sectors and growth in research and development activity and in-vitro diagnostic testing. Merck and Swiss diagnostics group Roche Holding are moving some of their reagent production closer to their Chinese customers. In 2023, Merck announced plans to invest €70mil (US$81mil) in a reagents facility in Nantong that is on track to begin operations next year. Merck declined to comment on any short-term shifts in ordering patterns from Chinese customers. 'The decision to invest in reagent manufacturing in Nantong reflects our commitment to supporting the growing needs of life science and biopharma customers in China and the broader Asia-Pacific region,' it said in a statement. Roche is expanding production, laboratory and logistics facilities from 2028 in Suzhou, where it produces reagents for diagnostic systems, the company said in a statement. The expansion will help it meet increasing demand for diagnostic solutions in China and parts of Asia-Pacific, it said. — Reuters Andrew Silver writes for Reuters. The views expressed here are the writer's own.
